The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Hosseini, Elahe Seyed; Nikkhah, Ali; Sotudeh, Amir; Zarei, Marziyeh Alizadeh; Izadpanah, Fatemeh; Nikzad, Hossein

doi:10.1186/s12935-021-02125-1

Cited by 5 publications

(4 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…lncRNAs have been the focus of intense recent study because they have been found to play a role in cancer development and progression, specifically in cancer immunity, metabolism, and metastasis, through their regulation of gene expression at the transcriptional and translational level 58 . Moreover, dysregulation of lncRNA expression has been found to be associated with both the pathology of pancreatic cancer and patient survival 59 . It is therefore not surprising that our analyses showed that differential expression of lncRNA fragments in Vn96-isolated EVs provides good segregation of PDAC patients from non-affected individuals.…”

Section: Discussionmentioning

confidence: 99%

Small RNA sequencing analysis of peptide-affinity isolated plasma extracellular vesicles distinguishes pancreatic cancer patients from non-affected individuals

Roy¹,

Wajnberg²,

Boucher³

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) has a high fatality rate, mainly due to its asymptomatic nature until late-stage disease and therefore delayed diagnosis that leads to a lack of timely treatment intervention. Consequently, there is a significant need for better methods to screen populations that are at high risk of developing PDAC. Such advances would result in earlier diagnosis, more treatment options, and ultimately better outcomes for patients. Several recent studies have applied the concept of liquid biopsy, which is the sampling of a biofluid (such as blood plasma) for the presence of disease biomarkers, to develop screening approaches for PDAC; several of these studies have focused on analysis of extracellular vesicles (EVs) and their cargoes. While these studies have identified many potential biomarkers for PDAC that are present within EVs, their application to clinical practice is hindered by the lack of a robust, reproducible method for EV isolation and analysis that is amenable to a clinical setting. Our previous research has shown that the Vn96 synthetic peptide is indeed a robust and reproducible method for EV isolation that has the potential to be used in a clinical setting. We have therefore chosen to investigate the utility of the Vn96 synthetic peptide for this isolation of EVs from human plasma and the subsequent detection of small RNA biomarkers of PDAC by Next-generation sequencing (NGS) analysis. We find that analysis of small RNA from Vn96-isolated EVs permits the discrimination of PDAC patients from non-affected individuals. Moreover, analyses of all small RNA species, miRNAs, and lncRNA fragments are most effective at segregating PDAC patients from non-affected individuals. Several of the identified small RNA biomarkers have been previously associated with and/or characterized in PDAC, indicating the validity of our findings, whereas other identified small RNA biomarkers may have novel roles in PDAC or cancer in general. Overall, our results provide a basis for a clinically-amendable detection and/or screening strategy for PDAC using a liquid biopsy approach that relies on Vn96-mediated isolation of EVs from plasma.

show abstract

Section: Discussionmentioning

confidence: 99%

Small RNA sequencing analysis of peptide-affinity isolated plasma extracellular vesicles distinguishes pancreatic cancer patients from non-affected individuals

Roy¹,

Wajnberg²,

Boucher³

et al. 2023

Sci Rep

View full text Add to dashboard Cite

show abstract

“…Nevertheless, not all the actions and functions of lncRNA is yet known. Several studies in this area will help researchers in the future to lay the groundwork for ovarian cancer therapy, targeting the lncRNA directly [92].…”

Section: Use Of Biomarkers Obtained Through Liquid Biopsy As a Progno...mentioning

confidence: 99%

New insights of liquid biopsy in ovarian cancer

Panagiotis¹,

Alina²,

Maria³

et al. 2022

J Genet Med Gene Ther

View full text Add to dashboard Cite

Through the development of new analysis technologies, many issues regarding the approach to tumoral diseases have been elucidated. With analytical assays developed in the last years, various omics technologies have evolved in such a manner that the characteristics of tumor cells and products can be evaluated (assessed) in the bloodstream of cancer patients at different times. Ovarian Cancer (OC) is one of the most difficult to diagnose umors, with low survival rates due to the high heterogeneity of these diseases that are distinct in terms of etiology and molecular characteristics, but which simply share an anatomical appearance. Recent findings have indicated that several types of ovarian cancer classified into different histotypes are in fact derived from non-ovarian issues and share few molecular similarities. Within this context, ovarian cancer screening and diagnosis can be made through the evaluation of circulating tumor cells in peripheral blood using liquid biopsy technologies. Advances in the study of various molecules analyzed by liquid biopsy have shown that elucidation of intratumoural and intertumoural heterogeneity and spatial and temporal tumor evolution could be traced by serial blood tests rather than by histopathological analyses of tissue samples from a primary tumor. Therefore, evaluation of some molecules such as circulating tumor cells (CTC), circulating tumor DNA (ctDNA), circulating cell-free RNA (non-coding and mRNA, extracellular vesicles), tumor-educated platelets or different miRNAs using liquid biopsy could lead to improvement of patient management.

show abstract

“…Pancreatic cancer (PC), as a malignancy of the abdominal digestive system, has a critical high fatality rate with a 5-year survival rate of less than 10% [ 1 ]. Patients with PC have a median survival time of 3–6 months [ 2 ]. For the past few years, the incidence of PC has been on the rise, with an average of 216,000 new cases reported worldwide each year, resulting in more than 200,000 deaths a year [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

“…Similarly, H19 was markedly overexpressed in PC tissues, the level of expression was positively correlated with histopathological grade and malignant phenotype including aggressiveness [ 13 ]. Furthermore, lncRNAs are widely detected in body fluids consisting of blood, saliva, urine, and even pancreatic juice [ 2 ]. Therefore, as a novel biomarker closely related to tumor diagnosis, targeted therapy, and improvement of patient prognosis, it is particularly necessary to further explore the function as well as the corresponding mechanism of lncRNA in PC.…”

Section: Introductionmentioning

confidence: 99%

The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer

Liu

et al. 2022

Cell Death Discov.

View full text Add to dashboard Cite

Non-coding RNAs (ncRNAs), which occupy the vast majority of human transcripts are known for their inability to encode proteins. NcRNAs consist of a diverse range of RNA species, including long non-coding RNAs (lncRNAs), which have significant meaning for epigenetic modification, post-transcriptional regulation of target genes, molecular interference, etc. The dysregulation of ncRNAs will mediate the pathogenesis of diverse human diseases, like cancer. Pancreatic cancer, as one of the most lethal malignancies in the digestive system that is hard to make a definite diagnosis at an early clinicopathological stage with a miserable prognosis. Therefore, the identification of potential and clinically applicable biomarker is momentous to improve the overall survival rate and positively ameliorate the prognosis of patients with pancreatic carcinoma. LncRNAs as one kind of ncRNAs exert multitudinous biological functions, and act as molecular sponges, relying on microRNA response elements (MREs) to competitively target microRNAs (miRNAs), thereby attenuating the degradation or inhibition of miRNAs to their own downstream protein-coding target genes, also thus regulating the initiation and progression of neoplasms. LncRNAs, which emerge aforementioned function are called competing endogenous RNAs (ceRNAs). Consequently, abundant research of lncRNAs as potential biomarkers is of critical significance for the molecular diagnosis, targeted therapy, as well as prognosis monitoring of pancreatic cancer.

show abstract

The impact of LncRNA dysregulation on clinicopathology and survival of pancreatic cancer: a systematic review and meta-analysis (PRISMA compliant)

Cited by 5 publications

References 67 publications

Small RNA sequencing analysis of peptide-affinity isolated plasma extracellular vesicles distinguishes pancreatic cancer patients from non-affected individuals

Small RNA sequencing analysis of peptide-affinity isolated plasma extracellular vesicles distinguishes pancreatic cancer patients from non-affected individuals

New insights of liquid biopsy in ovarian cancer

The role of lncRNA-mediated ceRNA regulatory networks in pancreatic cancer

Contact Info

Product

Resources

About